Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
UCSD loses Alzheimer's research contract
Pharmaceutical giant Lilly shifts to USC, new home of alleged staff/data poacher
The financial repercussions of a controversial move by one of UC San Diego's top researchers to the University of Southern California appear to be surfacing.
Eli Lilly and Company, a global pharmaceutical giant, announced Tuesday (August 4) that it intends to end its contract with UCSD for research related to solanezumab, a prospective new early-stage Alzheimer's treatment drug.
Did Paul Aisen steal UCSD data?
The announcement comes in the wake of Alzheimer's specialist Paul Aisen leaving UCSD in order to start a San Diego-based research facility in conjunction with USC. The move has been the subject of litigation by UCSD, who claim that Aisen, while still on the university's payroll, called meetings for the purpose of poaching staff to join him in his planned exodus. Aisen and others are also accused of stealing data and property from UCSD prior to the move.
It has been reported that Aisen was allegedly offered $8 million by USC to set up his new facility if he agreed to move, as well as a $500,000 annual salary.
"From the outset of this unfortunate dispute, Lilly has publicly stated that the company's objectives are to maintain the safety of the A4 participants, ensure scientific and data integrity for the study and maintain our obligations as the regulatory sponsor," reads a release from Lilly announcing the termination of UCSD's study oversight.
Lilly tries to assuage UCSD
"The A4 study will continue uninterrupted as the company initiates discussions with the University of Southern California about transitioning management and oversight of the study, while the company will simultaneously work with UCSD on a transition plan."
Phyllis Ferrell, Lilly's Alzheimer's platform leader, adds that the company "has many ongoing collaborations with researchers at UCSD" and that "nothing in our decision concerning the A4 study should be read to reflect any diminished enthusiasm in working with UCSD."
Here's something you might be interested in.
UCSD loses Alzheimer's research contract
Pharmaceutical giant Lilly shifts to USC, new home of alleged staff/data poacher
UCSD loses Alzheimer's research contract
Pharmaceutical giant Lilly shifts to USC, new home of alleged staff/data poacher
The financial repercussions of a controversial move by one of UC San Diego's top researchers to the University of Southern California appear to be surfacing.
Eli Lilly and Company, a global pharmaceutical giant, announced Tuesday (August 4) that it intends to end its contract with UCSD for research related to solanezumab, a prospective new early-stage Alzheimer's treatment drug.
Did Paul Aisen steal UCSD data?
The announcement comes in the wake of Alzheimer's specialist Paul Aisen leaving UCSD in order to start a San Diego-based research facility in conjunction with USC. The move has been the subject of litigation by UCSD, who claim that Aisen, while still on the university's payroll, called meetings for the purpose of poaching staff to join him in his planned exodus. Aisen and others are also accused of stealing data and property from UCSD prior to the move.
It has been reported that Aisen was allegedly offered $8 million by USC to set up his new facility if he agreed to move, as well as a $500,000 annual salary.
"From the outset of this unfortunate dispute, Lilly has publicly stated that the company's objectives are to maintain the safety of the A4 participants, ensure scientific and data integrity for the study and maintain our obligations as the regulatory sponsor," reads a release from Lilly announcing the termination of UCSD's study oversight.
Lilly tries to assuage UCSD
"The A4 study will continue uninterrupted as the company initiates discussions with the University of Southern California about transitioning management and oversight of the study, while the company will simultaneously work with UCSD on a transition plan."
Phyllis Ferrell, Lilly's Alzheimer's platform leader, adds that the company "has many ongoing collaborations with researchers at UCSD" and that "nothing in our decision concerning the A4 study should be read to reflect any diminished enthusiasm in working with UCSD."
Comments